CAD 2.35
(0.43%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 1.56 Million CAD | -27.95% |
2022 | 2.16 Million CAD | -16.3% |
2021 | 2.59 Million CAD | -87.61% |
2020 | 20.9 Million CAD | 15.5% |
2019 | 18.09 Million CAD | 1085.2% |
2018 | 1.52 Million CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | -100.0% |
2015 | 846.46 Thousand CAD | 28.15% |
2014 | 660.51 Thousand CAD | 28.0% |
2013 | 516.01 Thousand CAD | 0.0% |
2012 | - CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | 0.0% |
2008 | - CAD | 0.0% |
2007 | - CAD | 0.0% |
2006 | - CAD | 0.0% |
2005 | - CAD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q3 | 1.07 Million CAD | -14.02% |
2024 Q2 | 1.25 Million CAD | -8.83% |
2024 Q1 | 1.37 Million CAD | -11.87% |
2023 Q1 | 1.99 Million CAD | -7.84% |
2023 Q2 | 1.86 Million CAD | -6.49% |
2023 Q3 | 1.68 Million CAD | -10.01% |
2023 FY | 1.56 Million CAD | -27.95% |
2023 Q4 | 1.56 Million CAD | -7.1% |
2022 FY | 2.16 Million CAD | -16.3% |
2022 Q2 | 2.32 Million CAD | -5.19% |
2022 Q3 | 2.24 Million CAD | -3.24% |
2022 Q1 | 2.45 Million CAD | -5.35% |
2022 Q4 | 2.16 Million CAD | -3.6% |
2021 Q4 | 2.59 Million CAD | -86.91% |
2021 Q1 | 19.94 Million CAD | -4.6% |
2021 Q2 | 20.38 Million CAD | 2.21% |
2021 Q3 | 19.79 Million CAD | -2.86% |
2021 FY | 2.59 Million CAD | -87.61% |
2020 Q3 | 21.53 Million CAD | -1.44% |
2020 Q2 | 21.85 Million CAD | 3.5% |
2020 FY | 20.9 Million CAD | 15.5% |
2020 Q1 | 21.11 Million CAD | 16.68% |
2020 Q4 | 20.9 Million CAD | -2.96% |
2019 Q3 | 17.8 Million CAD | -2.12% |
2019 FY | 18.09 Million CAD | 1085.2% |
2019 Q2 | 18.19 Million CAD | 6.33% |
2019 Q1 | 17.1 Million CAD | 1020.52% |
2019 Q4 | 18.09 Million CAD | 1.63% |
2018 Q3 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2018 FY | 1.52 Million CAD | 0.0% |
2018 Q4 | 1.52 Million CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2016 Q3 | - CAD | -100.0% |
2016 Q2 | 765.54 Thousand CAD | -15.03% |
2016 Q4 | - CAD | 0.0% |
2016 FY | - CAD | -100.0% |
2016 Q1 | 900.93 Thousand CAD | 6.44% |
2015 Q1 | 703.59 Thousand CAD | 6.52% |
2015 Q4 | 846.46 Thousand CAD | 8.5% |
2015 FY | 846.46 Thousand CAD | 28.15% |
2015 Q2 | 748.03 Thousand CAD | 6.32% |
2015 Q3 | 780.14 Thousand CAD | 4.29% |
2014 FY | 660.51 Thousand CAD | 28.0% |
2014 Q1 | 549.32 Thousand CAD | 6.45% |
2014 Q3 | 621.48 Thousand CAD | 6.42% |
2014 Q4 | 660.51 Thousand CAD | 6.28% |
2014 Q2 | 584.01 Thousand CAD | 6.32% |
2013 Q1 | - CAD | 0.0% |
2013 Q4 | 516.01 Thousand CAD | 0.0% |
2013 FY | 516.01 Thousand CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 FY | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2011 Q1 | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2010 Q4 | - CAD | 0.0% |
2010 FY | - CAD | 0.0% |
2010 Q1 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2009 Q4 | - CAD | 0.0% |
2009 Q3 | - CAD | 0.0% |
2009 Q2 | - CAD | 0.0% |
2009 Q1 | - CAD | 0.0% |
2009 FY | - CAD | 0.0% |
2008 Q2 | - CAD | 0.0% |
2008 Q4 | - CAD | 0.0% |
2008 Q3 | - CAD | 0.0% |
2008 FY | - CAD | 0.0% |
2008 Q1 | - CAD | 0.0% |
2007 Q3 | - CAD | 0.0% |
2007 FY | - CAD | 0.0% |
2007 Q1 | - CAD | 0.0% |
2007 Q4 | - CAD | 0.0% |
2007 Q2 | - CAD | 0.0% |
2006 Q3 | - CAD | 0.0% |
2006 Q2 | - CAD | 0.0% |
2006 Q1 | - CAD | 0.0% |
2006 Q4 | - CAD | 0.0% |
2006 FY | - CAD | 0.0% |
2005 FY | - CAD | 0.0% |
2005 Q1 | - CAD | 0.0% |
2005 Q2 | - CAD | 0.0% |
2005 Q4 | - CAD | 0.0% |
2005 Q3 | - CAD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Arch Biopartners Inc. | 5.01 Million CAD | 68.852% |
Hemostemix Inc. | 4.32 Million CAD | 63.844% |
Universal Ibogaine Inc. | 1.73 Million CAD | 10.083% |
Kane Biotech Inc. | 8.27 Million CAD | 81.12% |
MedMira Inc. | 9.27 Million CAD | 83.147% |
Marvel Biosciences Corp. | 1 Million CAD | -56.247% |
NervGen Pharma Corp. | 197.19 Thousand CAD | -692.365% |
XORTX Therapeutics Inc. | 15.17 Thousand CAD | -10194.953% |